Published in Trends Analyt Chem on February 01, 2010
Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One (2010) 3.64
Salivary biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol Rev (2013) 1.34
A critical appraisal of techniques, software packages, and standards for quantitative proteomic analysis. OMICS (2012) 1.25
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics (2013) 1.09
World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research. Fertil Steril (2014) 0.98
Salivary biomarkers for detection of oral squamous cell carcinoma - current state and recent advances. Curr Oral Health Rep (2014) 0.96
Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. PLoS One (2014) 0.95
Age-dependent changes in the cerebrospinal fluid proteome by slow off-rate modified aptamer array. Am J Pathol (2011) 0.92
Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation. J Transl Med (2010) 0.85
Screening and identification of apolipoprotein A-I as a potential hepatoblastoma biomarker in children, excluding inflammatory factors. Oncol Lett (2015) 0.82
Recommendations and Standardization of Biomarker Quantification Using NMR-Based Metabolomics with Particular Focus on Urinary Analysis. J Proteome Res (2016) 0.79
Serum biomarkers reveal long-term cardiac injury in isoproterenol-treated African green monkeys. J Proteome Res (2013) 0.79
Advancing Point-of-Care (PoC) Testing Using Human Saliva as Liquid Biopsy. Diagnostics (Basel) (2017) 0.78
Plasma proteomic profiling in HIV-1 infected methamphetamine abusers. PLoS One (2012) 0.78
Efficient separations of intact proteins using slip-flow with nano-liquid chromatography-mass spectrometry. Anal Chem (2014) 0.77
A comparative study of glycoproteomes in androgen-sensitive and -independent prostate cancer cell lines. Mol Cell Biochem (2013) 0.76
Oral Biofluid Biomarker Research: Current Status and Emerging Frontiers. Diagnostics (Basel) (2016) 0.75
Positional cloning of the mouse obese gene and its human homologue. Nature (1994) 38.85
The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics (2002) 16.08
Searching for peptide ligands with an epitope library. Science (1990) 10.75
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol Cell Proteomics (2007) 6.96
A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci U S A (1991) 6.13
Cystic fibrosis. Lancet (2009) 5.40
Obese, a new mutation in the house mouse. J Hered (1950) 5.33
Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature (1991) 5.30
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4.18
Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol (1993) 4.10
Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol (2001) 3.58
Decision tree-driven tandem mass spectrometry for shotgun proteomics. Nat Methods (2008) 3.53
Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1992) 2.98
Functional proteomic profiling of AML predicts response and survival. Blood (2008) 2.90
Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D gel- or LC-MALDI TOF/TOF. J Proteome Res (2006) 2.73
Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci U S A (1979) 2.66
Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. PLoS One (2008) 2.65
Next-generation high-density self-assembling functional protein arrays. Nat Methods (2008) 2.46
Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. J Proteome Res (2005) 2.22
Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics (2003) 2.04
beta-Lipotropin as a prohormone for the morphinomimetic peptides endorphins and enkephalins. Proc Natl Acad Sci U S A (1976) 1.79
Proteomics. Proteomics ponders prime time. Science (2008) 1.72
The proteomic analysis of primary cortical astrocyte cell culture after morphine administration. J Proteome Res (2009) 1.55
Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity. Proc Natl Acad Sci U S A (1992) 1.54
Multiple reaction monitoring as a method for identifying protein posttranslational modifications. J Biomol Tech (2005) 1.49
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J (2009) 1.46
Human combinatorial antibody libraries to hepatitis B surface antigen. Proc Natl Acad Sci U S A (1992) 1.43
Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res (2007) 1.35
Protein arrays as tools for serum autoantibody marker discovery in cancer. J Proteomics (2009) 1.31
Protein microarrays: promising tools for proteomic research. Proteomics (2003) 1.27
Different immunoaffinity fractionation strategies to characterize the human plasma proteome. J Proteome Res (2006) 1.23
Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation. Br J Cancer (2008) 1.22
Targeted mass spectrometric strategy for global mapping of ubiquitination on proteins. Rapid Commun Mass Spectrom (2007) 1.21
Efficient and specific removal of albumin from human serum samples. Mol Cell Proteomics (2003) 1.20
The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides. Biotechniques (1992) 1.18
Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. J Proteome Res (2009) 1.18
The pitfalls of proteomics experiments without the correct use of bioinformatics tools. Proteomics (2006) 1.17
Global proteome discovery using an online three-dimensional LC-MS/MS. J Proteome Res (2005) 1.14
A stress test for mass spectrometry-based proteomics. Nat Methods (2009) 1.11
Analysis of phosphorylation sites on focal adhesion kinase using nanospray liquid chromatography/multiple reaction monitoring mass spectrometry. Rapid Commun Mass Spectrom (2006) 1.08
Methods for samples preparation in proteomic research. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 1.08
Absolute quantification of phosphorylation on the kinase activation loop of cellular focal adhesion kinase by stable isotope dilution liquid chromatography/mass spectrometry. Anal Chem (2009) 1.07
Biomarkers of HIV-1 associated dementia: proteomic investigation of sera. Proteome Sci (2009) 1.06
Assessment of albumin removal from an immunoaffinity spin column: critical implications for proteomic examination of the albuminome and albumin-depleted samples. Proteomics (2009) 1.05
Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res (2009) 1.02
Comparison of different signal thresholds on data dependent sampling in Orbitrap and LTQ mass spectrometry for the identification of peptides and proteins in complex mixtures. J Am Soc Mass Spectrom (2009) 1.01
Enrichment of low-abundant serum proteins by albumin/immunoglobulin G immunoaffinity depletion under partly denaturing conditions. Electrophoresis (2005) 1.01
Direct determination of phosphorylated intracellular anabolites of stavudine (d4T) by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2001) 1.00
Experimental design and analysis of antibody microarrays: applying methods from cDNA arrays. Cancer Res (2005) 0.99
Serum microarrays for large scale screening of protein levels. Mol Cell Proteomics (2005) 0.98
Human immunodeficiency virus-mononuclear phagocyte interactions: emerging avenues of biomarker discovery, modes of viral persistence and disease pathogenesis. Curr HIV Res (2006) 0.96
In situ synthesis of protein arrays. Curr Opin Biotechnol (2008) 0.95
Protein microarrays: catching the proteome. Mech Ageing Dev (2005) 0.94
Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment. Proteomics Clin Appl (2008) 0.94
Pharmacology and pharmacogenetics of chemotherapeutic agents. Cancer Invest (2009) 0.94
Overview of evidence-based medicine: challenges for evidence-based laboratory medicine. Clin Chem (2001) 0.94
Plasma proteome analysis for anti-obesity and anti-diabetic potentials of chitosan oligosaccharides in ob/ob mice. Proteomics (2009) 0.93
Identification of polyubiquitin binding proteins involved in NF-kappaB signaling using protein arrays. Biochim Biophys Acta (2009) 0.92
Protein-protein interaction studies on protein arrays: effect of detection strategies on signal-to-background ratios. Anal Biochem (2009) 0.92
Proteomic analysis of archival breast cancer serum. Cancer Genomics Proteomics (2009) 0.91
On-chip protein synthesis for making microarrays. Methods Mol Biol (2006) 0.91
Optimizing the difference gel electrophoresis (DIGE) technology. Methods Mol Biol (2008) 0.90
Mass spectrometry-based clinical proteomics profiling: current status and future directions. Expert Rev Proteomics (2009) 0.87
Multidimensional protein fractionation using ProteomeLab PF 2D for profiling amyotrophic lateral sclerosis immunity: A preliminary report. Proteome Sci (2008) 0.87
Chemogenomics: drug discovery's panacea? Mol Biosyst (2006) 0.86
Miniaturized parallelized sandwich immunoassays. Methods Mol Biol (2008) 0.85
Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS. Oncol Rep (2009) 0.85
SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem (2009) 0.84
Proteomics/peptidomics tools to find CSF biomarkers for neurodegenerative diseases. Front Biosci (Landmark Ed) (2009) 0.84
Protein microarrays as an application for disease biomarkers. Proteomics Clin Appl (2009) 0.83
Vasoactive intestinal polypeptide and related peptides. Isolation and chemistry. Ann N Y Acad Sci (1988) 0.82
Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signaling. Proteomics (2008) 0.81
Application of proteomics in cancer gene profiling: two-dimensional difference in gel electrophoresis (2D-DIGE). Methods Mol Biol (2010) 0.81
Start-to-end processing of two-dimensional gel electrophoretic images. J Chromatogr A (2007) 0.80
Digital microfluidics for automated proteomic processing. J Vis Exp (2009) 0.79
Identification of protein kinase substrates by proteomic approaches. Expert Rev Proteomics (2008) 0.78
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One (2008) 1.99
Nitrated alpha-synuclein-activated microglial profiling for Parkinson's disease. J Neurochem (2007) 1.35
Cerebrospinal fluid proteomic profiling of HIV-1-infected patients with cognitive impairment. J Proteome Res (2007) 1.35
CSF proteomic fingerprints for HIV-associated cognitive impairment. J Neuroimmunol (2007) 1.16
Nitrated alpha-synuclein and microglial neuroregulatory activities. J Neuroimmune Pharmacol (2008) 1.15
The Scl1 protein of M6-type group A Streptococcus binds the human complement regulatory protein, factor H, and inhibits the alternative pathway of complement. Mol Microbiol (2007) 1.14
Cytoskeletal protein transformation in HIV-1-infected macrophage giant cells. J Immunol (2007) 1.13
Biomarkers of HIV-1 associated dementia: proteomic investigation of sera. Proteome Sci (2009) 1.06
HIV-1 infected monocyte-derived macrophages affect the human brain microvascular endothelial cell proteome: new insights into blood-brain barrier dysfunction for HIV-1-associated dementia. J Neuroimmunol (2007) 1.05
Identification of two small regulatory RNAs linked to virulence in Brucella abortus 2308. Mol Microbiol (2012) 1.01
Proteomic modeling for HIV-1 infected microglia-astrocyte crosstalk. PLoS One (2008) 0.99
Sera proteomic biomarker profiling in HIV-1 infected subjects with cognitive impairment. Proteomics Clin Appl (2008) 0.94
Comparison of 4-plex to 8-plex iTRAQ quantitative measurements of proteins in human plasma samples. J Proteome Res (2012) 0.93
HIV-1 transforms the monocyte plasma membrane proteome. Cell Immunol (2009) 0.93
Spatial learning impairment, enhanced CDK5/p35 activity, and downregulation of NMDA receptor expression in transgenic mice expressing tau-tubulin kinase 1. J Neurosci (2008) 0.93
HIV-1-infected astrocytes and the microglial proteome. J Neuroimmune Pharmacol (2008) 0.92
Opposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophages. Retrovirology (2015) 0.92
Syntheses of click PEG-dexamethasone conjugates for the treatment of rheumatoid arthritis. Biomacromolecules (2010) 0.90
Quantitative proteomics by SWATH-MS reveals altered expression of nucleic acid binding and regulatory proteins in HIV-1-infected macrophages. J Proteome Res (2014) 0.89
Pulsed stable isotope labeling of amino acids in cell culture uncovers the dynamic interactions between HIV-1 and the monocyte-derived macrophage. J Proteome Res (2011) 0.88
Multidimensional protein fractionation using ProteomeLab PF 2D for profiling amyotrophic lateral sclerosis immunity: A preliminary report. Proteome Sci (2008) 0.87
Proteomic analyses of monocytes obtained from Hispanic women with HIV-associated dementia show depressed antioxidants. Proteomics Clin Appl (2010) 0.87
Proteomic analysis of early HIV-1 nucleoprotein complexes. J Proteome Res (2013) 0.86
Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation. J Transl Med (2010) 0.85
VprBP binds full-length RAG1 and is required for B-cell development and V(D)J recombination fidelity. EMBO J (2011) 0.84
Proteolytic processing of SDF-1α by matrix metalloproteinase-2 impairs CXCR4 signaling and reduces neural progenitor cell migration. Protein Cell (2012) 0.83
Proteomic fingerprinting of HIV-1-infected human monocyte-derived macrophages: a preliminary report. J Neuroimmunol (2004) 0.82
Plasma proteomic profiling in HIV-1 infected methamphetamine abusers. PLoS One (2012) 0.78
Changes in the plasma proteome follows chronic opiate administration in simian immunodeficiency virus infected rhesus macaques. Drug Alcohol Depend (2011) 0.78
Elucidating protein inter- and intramolecular interacting domains using chemical cross-linking and matrix-assisted laser desorption ionization-time of flight/time of flight mass spectrometry. Anal Biochem (2011) 0.77
Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme--phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis. Oncotarget (2015) 0.75
Calpain and proteasomal regulation of antiretroviral zinc finger protein OTK18 in human macrophages: visualization in live cells by intramolecular FRET. J Neuroimmune Pharmacol (2008) 0.75
Proteomics and HIV. Proteomics Clin Appl (2016) 0.75